Search alternatives:
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
less decrease » teer decrease (Expand Search), levels decreased (Expand Search), largest decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
less decrease » teer decrease (Expand Search), levels decreased (Expand Search), largest decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
921
Internal validation by cross-validation.
Published 2024“…<div><p>Locomotive Syndrome (LS) is defined by decreased walking and standing abilities due to musculoskeletal issues. …”
-
922
<b> </b> Rate of brain weight to body weight in different experimental groups. AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate....
Published 2025“…AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate. …”
-
923
Survival function analysis of mortality for Viral load status and Treatment Interruption status.
Published 2025Subjects: -
924
-
925
-
926
Survival function analysis of treatment Interruption for Viral load status and BMI status.
Published 2025Subjects: -
927
Survival function analysis of viral suppression for BMI status and Treatment Interruption status.
Published 2025Subjects: -
928
-
929
-
930
-
931
-
932
-
933
-
934
-
935
Survival function analysis for LTFU according to Viral Load status and BMI status.
Published 2025Subjects: -
936
-
937
Annual incidence rate per 100 person-years trend for ART treatment outcomes.
Published 2025Subjects: -
938
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
939
-
940